245 related articles for article (PubMed ID: 26858523)
1. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.
Guariglia R; Martorelli MC; Lerose R; Telesca D; Milella MR; Musto P
Biologics; 2016; 10():1-8. PubMed ID: 26858523
[TBL] [Abstract][Full Text] [Related]
2. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L; Baser O; Kutikova L; Page JH; Barron R
Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
Volovat C; Bondarenko I; Gladkov O; Buchner A; Lammerich A; Müller U; Bias P
Support Care Cancer; 2016 Dec; 24(12):4913-4920. PubMed ID: 27501966
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
[TBL] [Abstract][Full Text] [Related]
9. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
Bondarenko IM; Bias P; Buchner A
Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
[TBL] [Abstract][Full Text] [Related]
10. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC; Szabo E; Gabriel S; Klastersky J; Tomey O; Mueller U; Schwartzberg L; Tang B
J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies.
Gessner C; Potthoff K; Frost N
Oncol Res Treat; 2021; 44(3):93-102. PubMed ID: 33477145
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
Petru E; Singer CF; Polterauer S; Galid A; Schauer C; Klocker J; Seifert M; Reinthaller A; Benedicic C; Hubalek M; Hefler L; Marth C; Scholl-Firon T; Bogner G; Zeimet AG
Wien Med Wochenschr; 2015 Oct; 165(19-20):387-94. PubMed ID: 26471371
[TBL] [Abstract][Full Text] [Related]
15. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M; Boccia R; Leonard R; Camps C; Campone M; Choquet S; Danova M; Glaspy J; Hus I; Link H; Sliwa T; Tesch H; Valero V
Support Care Cancer; 2017 Nov; 25(11):3295-3304. PubMed ID: 28842778
[TBL] [Abstract][Full Text] [Related]
16. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
Link H; Thompson SF; Tian M; Haas JS; Meise D; Maas C; Dimitrov S
Support Care Cancer; 2022 Nov; 30(11):9317-9327. PubMed ID: 36076105
[TBL] [Abstract][Full Text] [Related]
17. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.
Volovat C; Bondarenko IM; Gladkov OA; Elsässer R; Buchner A; Bias P; Müller U
Springerplus; 2015; 4():316. PubMed ID: 26155455
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.
Akpo EIH; Jansen IR; Maes E; Simoens S
Front Pharmacol; 2017; 8():614. PubMed ID: 28955224
[No Abstract] [Full Text] [Related]
20. The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
Holubec L; Polivka J; Lisnerova L; Kubikova T; Safanda M
In Vivo; 2017; 31(3):303-306. PubMed ID: 28438855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
